A mitochondrial-derived peptide, encoded in mitochondrial DNA. Studied as a metabolic exercise mimetic — insulin sensitivity, energy regulation, longevity research.
MOTS-c is a 16-amino-acid peptide with a genuinely unusual origin: it's encoded within the 12S rRNA region of mitochondrial DNA, not the cell's nuclear genome. Most signalling peptides — everything else in this catalog — come from nuclear genes. MOTS-c is one of a small family of mitochondrial-derived peptides (MDPs), discovered by Changhan David Lee's lab at the University of Southern California in 2015. Its mitochondrial origin is central to its proposed biology: a retrograde stress signal that communicates the cell's metabolic state from the mitochondria outward to the nucleus and other tissues.
MOTS-c behaves in research as a metabolic "exercise mimetic" — it's naturally upregulated during physical exercise, translocates to the cell nucleus under metabolic stress, and activates AMPK-pathway genes involved in energy regulation and stress adaptation. That exercise-linked biology is exactly why WADA added it to the Prohibited List in 2024, under the same section that governs other performance-enhancing metabolic modulators.
The honest evidence picture: preclinical data (rodent and cell studies) is genuinely strong — improved insulin sensitivity, reduced obesity markers, diabetes prevention effects, and anti-aging signals across multiple animal models. Human data is thinner. The most relevant human-adjacent data point comes from CB4211, a MOTS-c analog developed by CohBar, which showed safety and reduced liver fat markers (ALT and AST both down double digits) in a Phase 1 trial in obese subjects with fatty liver — but CohBar's Phase 2 development was subsequently discontinued, and no MOTS-c-based drug has since advanced further in the clinical pipeline.
MOTS-c's mechanism is genuinely distinct from every GH-axis or repair peptide in this catalog — it operates through cellular energy-sensing machinery rather than a hormone receptor cascade.
MOTS-c's research profile splits cleanly into strong preclinical signal and a much thinner human evidence base — worth stating plainly rather than blurring the two together.
MOTS-c's stacking logic is different from the GHRH-family pairings elsewhere in this catalog — it's not about receptor complementarity, but about combining distinct mitochondrial and metabolic mechanisms for broader longevity research coverage.
Both MOTS-c and Humanin belong to the same unusual family — peptides encoded in mitochondrial DNA rather than the nuclear genome — but they act through distinct mechanisms, which is the basis for pairing them in mitochondrial longevity research.
Why they're discussed together: both are mitochondrial-derived peptides studied in longevity research, but MOTS-c's research focus is metabolic/energy signalling while Humanin's is cytoprotection and cell survival — complementary angles on mitochondrial health rather than the same mechanism twice.
A second common pairing in mitochondrial longevity research: NAD+ is the coenzyme substrate mitochondria need for energy metabolism and DNA repair, while MOTS-c is a signalling peptide that modulates how cells respond to metabolic stress. One supplies raw material for mitochondrial function, the other modulates the signalling around it — a substrate-plus-signal combination rather than two compounds competing for the same job.
MOTS-c's human clinical evidence base is thin relative to its preclinical promise — stated plainly rather than overstated. The closest human data (CB4211) is a related analog compound, not MOTS-c itself.